Trials / Terminated
TerminatedNCT00893984
Alternative in Beta Blocker Intolerance: The ABBI Trial
Alternative in Beta Blocker Intolerance; the ABBI Trial
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Minneapolis Heart Institute Foundation · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
In this study the investigators will assess the tolerance of Nebivolol (Bystolic) in cardiovascular patients who are not able to tolerate conventional beta blockers. A side effect profile will be tracked and compared with previous beta blocker use. The investigators hypothesize that Bystolic will be tolerated by many patients who are intolerant of conventional blockers.
Detailed description
Patients who have been prescribed standard beta blockers but were unable to tolerate them due to side effects will be studied. They will take a new beta blocker, Nebivolol (Bystolic) for 30 days, if tolerated. Side effects will be tracked and compared to previous.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nebivolol | Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control. |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2009-05-06
- Last updated
- 2019-08-06
- Results posted
- 2019-07-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00893984. Inclusion in this directory is not an endorsement.